Fulgent Genetics, Inc. (FLGT) IPO PREVIEW

By Jon Lin

Key Facts About Fulgent Genetics, Inc.

  • 55 Employees, including 26 with a PhD or other advanced degree(s).
  • Ming Hsieh, 60, a self-made billionaire, Chinese-born American entrepreneur and philanthropist, is the President, CEO and Chairman of the company. Paul Kim, 49, is the Chief Financial Officer of the company, and Dr. Dr. Han Lin Gao, 50, is the Chief Scientific Officer (CSO).
  • Xi Long, a major investor, owns at least 5% of the company, according to the prospectus filed by the company.*
  • Credit Suisse and Piper Jaffray will serve as the lead underwriters. BTIG, LLC and Raymond James and Associates, Inc. will serve as additional underwriters.
  • Deloitte & Touche LLP is the auditor and Morrison & Foerster LLP will serve as the general counsel for this offering.

*Section 13(d) of the 1934 Act and Regulation 13D requires beneficial owners of more than 5% of a class of equity securities of a publicly traded company to file a report with the SEC.

We currently have only one such laboratory director with all of the required licenses, Dr. Han Lin Gao, who conducts this review and approval for each test we deliver. We are in the process of licensing additional laboratory directors to assist Dr. Gao, and we may need to hire more laboratory directors in the future to further scale our business. If we fail to hire additional personnel or otherwise develop our infrastructure sufficiently in advance of demand or if we fail to generate demand commensurate with our level of investment in our infrastructure, our business, prospects, financial condition and results of operations could be adversely affected.

^^ From the most recent (as of this writing) Prospectus which was filed on Sept. 26, 2016.

One of the major factors to consider before investing in any Non-accelerated Filer (company with a public float of less than $75 million) is the amount of employees a company has and the key personnel that are in charge of said company. Fulgent Genetics, Inc. is no exception to this rule and with 55 employees, there are no employees more responsible for the success of this company than these three below:

CEO of Fulgent Genetics, Inc.
CEO of Fulgent Genetics, Inc.

Ming Hsieh is a billionaire Chinese-born American entrepreneur and philanthropist. He is the founder of Cogent Systems in 1990. According to Forbes magazine, his estimated net worth exceeds $1.6 billion, ranking him the 198th richest person in America and 562nd among The World’s Richest People In 2006.

He graduated with a Bachelor of Science from the University of Southern California and received his masters in Electrical Engineering from USC in 1984. He also serves as a member of the board of directors of Fortinet, Inc., a network security company.

Paul Kim is the current Chief Financial Officer of Fulgent Genetics, Inc. and has had over 10 years of prior experience as a CFO for two large publicly trading technology companies.

Dr. Hanlin Gao (via Prospectus) is a founder of our genetic testing business, has served as Fulgent LLC’s Lab Director since February 2012, was appointed as Fulgent LLC’s Chief Scientific Officer in January 2016 and was appointed as our Lab Director and Chief Scientific Officer in September 2016. Dr. Gao’s prior experience includes service as Lab Director of both the DNA Sequencing Core Laboratory and Clinical Molecular Diagnostics Laboratory at City of Hope from 2004 until 2013. Dr. Gao completed his clinical molecular genetics training fellowship and post-doctoral fellowship at Harvard Medical School in 2004 prior to joining City of Hope. Dr. Gao received a M.S. in Immunology and an M.D. from Peking University and Inner Mongolia University for Nationalities in China in 1993 and 1990, respectively, as well as a Ph.D. in Microbiology, Immunology and Medical Genetics from The Ohio State University in 2001. Dr. Gao is board certified in clinical molecular genetics by the American Board of Medical Genetics, is a Fellow of the American College of Medical Genetics and Genomics and serves as a team leader for laboratory inspections by CAP.

The success of the Fulgent Genetics, Inc. will be based largely on its ability to hire and retain additional laboratory directors and specialists. Also, any loss of the top executives or key personnel will have an adverse effect on this company’s long term market performance.

Fulgent Genetics, Inc.’s scheduled IPO date is on 9/28/16 (Wednesday) and will be traded on the NASDAQ exchange under the symbol FLGT.

Wall Street Sponge utilises financial data provided by the S.E.C. and our writers use that information to form a basis for their analysis. Wall Street Sponge accepts no responsibility for the accuracy or completeness of any information herein contained.